Terns Pharmaceuticals: Revolutionizing Treatment Alternatives in the Pharmaceutical Industry

Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, has been making headway in the pharmaceutical industry. The company’s stock opened at $11.75 on Friday and has seen a 50-day moving average of $9.72 and a 200-day moving average of $7.84. Terns Pharmaceuticals went public with its stock offerings in June 2020 and has since witnessed its stock performance skyrocket to reach new heights.

Several equities research analysts have reviewed Terns Pharmaceuticals’ activities with the hope of providing investors with informed decisions concerning investing in the firm’s stocks. Two research analysts gave the stock a hold rating while three provided a buy rating for the biopharmaceutical firm’s shares. Bloomberg reported that Terns Pharmaceuticals had an average rating of “Moderate Buy” and an average price target of $14.00.

The latest news from Terns Pharmaceuticals came after last month’s financial results, revealing that the company made significant strides concerning quarterly earnings reports in March this year. For this quarter, Terns Pharmaceuticals reported an EPS of ($0.29), topping analyst projections by $0.11 as it rallied towards working on developing small-molecule single-agent and combination therapy options to address non-alcoholic steatohepatitis (NASH) and obesity.

Terns Pharmaceuticals is renowned for producing liver-distributed, non-bile acid farnesoid X receptor agonist (TERN-101). This drug is currently undergoing Phase IIa clinical trials targeting NASH treatment alongside vascular adhesion protein-1 inhibitor (TERN-201), which is testing for Cure NASH study patients to record any adverse effects against addiction, thus inhibiting disease progression.

Despite being relatively new to public trading share offers back in 2020, approximately two decades down the line from when It started immateriality; however, currently trading with annual highs at $12.42 and lows at $1.45 and its attempts to revolutionize treatment alternatives in the pharmaceutical industry, Terns Pharmaceuticals is shaping up to be a company that can’t be easily overlooked. The performance projection by different market analysts on this undoubtedly very fascinating firm’s upward trajectory warrants investor confidence in the stocks.

Terns Pharmaceuticals’ Q1 2023 Earnings Estimates Show Promise, But Hedge Funds and Institutional Investors Remain Cautiously Optimistic

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has recently come under the spotlight as research analysts from HC Wainwright raised their Q1 2023 earnings per share estimates for the company in a note issued to investors on March 29th. The new estimates predict that TERN will earn ($0.30) per share for the quarter, up from their initial estimate of ($0.47). While this news may seem impressive at first glance, it’s important to note that HC Wainwright maintains a “Neutral” rating and $11.00 price objective on the stock.

Despite this neutral outlook from HC Wainwright, several hedge funds and institutional investors have bought and sold shares of TERN in recent months. Vivo Capital LLC increased its position in shares of Terns Pharmaceuticals by 12.9% during the fourth quarter, while VR Adviser LLC purchased a new position in TERN during the third quarter valued at $21,839,000.

Driehaus Capital Management LLC also grew its holdings in Terns Pharmaceuticals by 43.6% during the fourth quarter and now owns over 2 million shares worth $23,357,000. Fairmount Funds Management LLC bought a new stake in shares of Terns Pharmaceuticals in the third quarter worth about $12,075,000.

Finally, Millennium Management LLC has raised its stake in shares of Terns Pharmaceuticals by an impressive 280.8% in the fourth quarter alone and now owns over 1 million shares worth $14,834,000.

As we look ahead to future earnings estimates for TERN, HC Wainwright projects Q2 2023 earnings at ($0.31) EPS and Q3 2023 earnings at ($0.32) EPS, followed by Q4 2023 earnings at ($0.27) EPS and FY2023 earnings at ($1.20) EPS. While these estimates may seem bleak, projections for FY2024-2027 show improved numbers with earnings per share ranging from ($1.49) to ($0.98).

In conclusion, while Terns Pharmaceuticals’ recent Q1 2023 earnings estimates may look promising at first glance with an increase in projected earnings per share, it’s important to take a closer look at the neutral rating and price objective set by HC Wainwright. However, several hedge funds and institutional investors have continued to show confidence in TERN through significant investments, and future earnings projections show potential for growth in the coming years.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source